In murine models of surgical implantation of TLR agonist-loaded gels into tumor resection sites, they observed no local tumor recurrence for at least one month and significantly improved survival, with the efficacy dependent on type I IFN signaling, NK cells, and CD4 and CD8 T cells (Fig. 7B). Here, CD4 is linked to neoplasm.